Mendelian randomization applied to cancer: What it has and has not achieved.

doi:10.1016/j.canep.2026.103182

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mendelian randomization applied to cancer: What it has and has not achieved.

Cancer epidemiology - 1 Oct 2026

Smith-Byrne K, Breeur Marie, Yarmolinsky James, Smith George Davey

Abstract excerpt

During the past decade, Mendelian randomisation (MR) has become one of the most frequently used tools for causal inference in modern epidemiology. By leveraging information on germline genetic variants as instruments for exposures, either using individual or summary-level data, MR applied to cancer outcomes aims to approximate features of a randomised controlled trial (RCT) whether to appraise evidence for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Genome-Wide Association Study
Share to Mendelian Randomization Analysis
Share to Neoplasms
Share to Risk Factors

Source

Open in PubMed

Identifiers

PMID: 42485848
DOI: 10.1016/j.canep.2026.103182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics